If you have Crohn's disease and you're on mesalazine — and you're still having 4 or 5 bad days a week, still dealing with cramping and urgent trips to the bathroom, still missing work or social plans because your gut is unpredictable — there's something important you may not have been told.
Mesalazine, also known as 5-aminosalicylic acid or 5-ASA (brand names: Asacol, Pentasa, Salofalk), is a first-line treatment for ulcerative colitis. Its evidence base for Crohn's disease is considerably weaker. Multiple systematic reviews and the major IBD clinical guidelines have consistently found limited support for mesalazine in Crohn's — particularly in moderate to severe disease. The fact that it is still widely prescribed for Crohn's in Canada reflects how diagnosis coding, formulary preferences, and limited gastroenterology access interact in the real world.
This does not mean your doctor made a reckless decision. But it does mean that if your Crohn's is not controlled on mesalazine, the correct response is not "let's stay on it a bit longer." It's a reconsideration of your entire treatment approach.
Before anything else: is your diagnosis definitely Crohn's disease, or could it be ulcerative colitis? These are both forms of inflammatory bowel disease but they are different conditions with different treatments. Crohn's can affect any part of the gastrointestinal tract; UC is limited to the colon. Mesalazine is highly effective for UC. If there's any diagnostic uncertainty, reviewing the original biopsy findings with a gastroenterologist is the right starting point.
Why mesalazine is often not the right medication for Crohn's
Mesalazine works by reducing local inflammation in the lining of the gut. In ulcerative colitis, where inflammation is consistently in the colon and rectum, this targeted approach is effective. In Crohn's disease, the situation is more complex:
- Crohn's can affect any layer of the bowel wall (transmural inflammation), while mesalazine primarily acts on the mucosal surface layer
- Crohn's can affect any part of the GI tract — small intestine, colon, or both — and mesalazine has poor coverage beyond the large intestine
- In Crohn's involving the small intestine (the most common location), mesalazine has essentially no evidence of benefit
- Major clinical practice guidelines, including those from the European Crohn's and Colitis Organisation (ECCO) and the American College of Gastroenterology, do not recommend mesalazine as first-line therapy for most presentations of Crohn's disease
Despite this, mesalazine continues to be prescribed for Crohn's in primary care settings and sometimes in specialist care — often because it is easily available, low-cost, and familiar. For mild colonic Crohn's, there may be some limited role. But for moderate to severe disease, or for small intestinal Crohn's, continuing on mesalazine when symptoms are uncontrolled is not the right approach.
What "not controlled" actually looks like — and why it matters
Gastroenterologists assess Crohn's disease activity using clinical scores — but in practical terms, uncontrolled Crohn's can look like any of the following:
- More than 3–4 loose stools per day
- Abdominal pain or cramping that affects daily activity
- Nocturnal symptoms (waking up to go to the bathroom)
- Fatigue disproportionate to what your other health factors explain
- Rectal bleeding (in colonic Crohn's)
- Weight loss or difficulty maintaining weight
- Ongoing need for steroids (prednisone) to manage flares — more than one course per year indicates the underlying disease is not being managed, only the flares
Faecal calprotectin is a stool test that measures inflammation in the bowel. It is objective, non-invasive, and one of the most useful tools for assessing whether Crohn's disease is actually active (inflamed) versus in remission. If your symptoms are ongoing and no one has ordered a calprotectin test, this is the single most important test to request. A high calprotectin confirms active inflammation and strengthens the case for stepping up treatment.
The treatment ladder for Crohn's disease — where mesalazine fits (and doesn't)
Induction with corticosteroids
Prednisone or budesonide to bring active Crohn's into remission quickly. This is a short-term tool — not a maintenance therapy. Repeated steroid use causes significant side effects.
Immunomodulators
Azathioprine, 6-mercaptopurine, or methotrexate. These suppress the immune response that drives Crohn's inflammation. They take 3–6 months to reach full effect and are used for maintenance.
Biologics (most important step for moderate-severe disease)
Anti-TNF agents: infliximab (Remicade), adalimumab (Humira). Also: vedolizumab (Entyvio), ustekinumab (Stelara), risankizumab (Skyrizi). These target the specific inflammatory pathways driving Crohn's. Major advance in Crohn's management in the last 20 years.
Combination therapy
Immunomodulator + biologic together. Evidence shows this is more effective than either alone in some patient profiles, particularly those with risk factors for antibody formation to biologic agents.
Mesalazine does not appear on this ladder for Crohn's disease — not because it's harmful, but because it doesn't meaningfully change the disease course for most Crohn's presentations.
What tests to request
If your Crohn's is not controlled, ask for these
- Faecal calprotectin — Confirms whether active bowel inflammation is present. Baseline for any treatment change discussion.
- CRP (C-reactive protein) — Blood marker of systemic inflammation. Often elevated in active Crohn's.
- Full blood count — Checks for anaemia (common in Crohn's due to blood loss, malabsorption, or inflammation).
- Iron, ferritin, B12, folate, Vitamin D — Crohn's frequently causes malabsorption of key nutrients. Deficiencies worsen symptoms independently and need separate management.
- Colonoscopy to assess mucosal healing — Symptom control is not the same as mucosal healing. Modern IBD management aims for mucosal healing (no visible inflammation on scope), not just symptom reduction. If you haven't had a scope since starting mesalazine, this is essential.
- Review of original biopsy — If there's any uncertainty about the diagnosis — Crohn's vs UC — reviewing the original tissue biopsy with a gastroenterologist clarifies this definitively.
The gastroenterologist wait time in Canada — and what to do in the meantime
In BC, Ontario, and Alberta, wait times to see a gastroenterologist for IBD can be 4 to 9 months for a new referral. If you are currently on mesalazine and symptomatic, this is a long time to wait without a treatment change — particularly when active Crohn's inflammation causes cumulative bowel damage over time.
In this window, there are concrete steps worth taking:
- Get a faecal calprotectin test ordered by your GP — this requires a gastroenterology consultation to action treatment change, but it arms you with objective data when you do get in
- Document your symptoms systematically — a daily symptom log (number of bowel movements, pain score, rectal bleeding, energy level) becomes clinical evidence
- Ask your GP to flag your referral as more urgent if symptoms are worsening — IBD referrals can sometimes be expedited with clinical documentation
- Consider an IBD specialist second opinion — a gastroenterologist who has reviewed your history, your original diagnosis, your current medication, and your test results can give you a clear recommendation for what to bring to your Canadian GI appointment
"My symptoms are not controlled on mesalazine — I'm having [X] loose stools per day with ongoing pain. I'd like a faecal calprotectin ordered, a review of my original biopsy to confirm Crohn's vs UC, and a discussion of whether stepping up to immunomodulators or biologics is appropriate. I don't want to stay on mesalazine if my disease is not responding."
Living with uncontrolled Crohn's is genuinely disabling — it affects work, relationships, travel, and mental health in ways that are hard to overstate. The treatment options available today are significantly more effective than they were a decade ago. If mesalazine isn't working, that's not a reason to accept the status quo. It's a reason to push harder for the right treatment.